永顺生物披露上半年直销收入占比及疫苗进展

Group 1 - The core viewpoint of the news is that Yongshun Bio has disclosed its direct sales revenue proportion for the first half of 2025, which is 33.14%, and has launched the inactivated vaccine for pigeon paramyxovirus, while the live vaccine for porcine pseudorabies is in the pre-launch preparation stage [1] - Recent financing balance shows a downward trend, indicating a short-term cautious sentiment among investors [1] Group 2 - In the past 7 trading days, Yongshun Bio's stock price has experienced a fluctuation range of 2.82%, with a slight overall oscillation [2] - On February 12, the stock closed at 9.01 yuan, down 2.38% for the day, with a highest price of 9.45 yuan and a lowest price of 9.00 yuan during this period [2] - The financing balance has been continuously declining, reflecting a cautious market sentiment [2]